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1. Introduction
   Extensive efforts to control malaria, supported with 
increased international funds and political commitment, 
have led to a significant reduction in the number of malaria 
cases in the last few years despite the unavailability of a 
vaccine. The achievements obtained are raising questions 
about whether a malaria vaccine is still required and 
whether global eradication of malaria could be a possibility.
1.1. Malaria control
   This has been seen even in some highly endemic African 
countries such as Eritrea, Rwanda and Zanzibar amongst 
others[1]. Even the burden of malaria in many countries 
throughout the world had been reduced, there were still 
219 million cases of malaria and about 660 000 deaths in 
African children in 2010[1]. It is believed that vaccines will 
be a necessary additional tool to the current measures but 
it is unlikely that they will be effective on their own. Figure 
1 illustrates the countries at the risk of malaria and their 
control status[2].
Figure 1. Country categorization by malaria control status and burden[2].
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1.2. Malaria vaccines
   Malaria vaccines would be useful to both who live in 
malaria endemic areas and who visit these areas for work, 
pleasure or missionary purposes. Vaccines have proved 
efficacious and cost-effective in controlling other diseases 
such as small pox and whooping cough. An ideal vaccine 
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would be one that offers a long-lasting immunity against all 
variants of each species.
2. Vaccine development
   Vaccine developers had been initially challenged to 
produce a vaccine by 2015 which offers 50% efficacy against 
severe disease and death from malaria with protection lasting 
longer than one year. The second goal is to produce a vaccine 
with 80% efficacy against severe disease by 2025 and it is still 
rather challenging[3]. 
   Vaccine development has not been easy due to a number of 
factors including:
   1. The complex life cycle of the malaria pathogen with 
different stage-specific antigens.
   2. Antigenic variation of proteins such as the PfEMP-1, 
which is a parasite protein expressed on the erythrocytes 
encoded by different var genes. The parasite regularly 
changes the expression of this var gene so that the infected 
erythrocyte escapes the recognition by host immunity[4]. 
   3. The complexity of the human immune system and the 
risks associated with vaccine development.
   However, the development of malaria vaccines is still 
thought to be feasible especially with a better understanding 
of the human immune process.
   Vaccines can be classified in three main groups: pre-
erythrocytic vaccines, blood stage vaccines, and transmission 
blocking vaccines.  
2.1. Pre-erythrocytic vaccines
   Pre-erythrocytic vaccines are essential to prevent 
sporozoites infecting beyond the liver stage[5]. These have 
included studies with the use of irradiated sporozoites, 
genetically altered parasites as well as the use of surface coat 
antigens of the parasite such as the circumsporozoite protein. 
The use of the latter is the most promising and in fact, the 
RTS,S malaria vaccine is in phase III trials. It is a hybrid 
molecule consisting of a recombinant antigen from part of the 
circumsporozoite protein fused to hepatitis B surface antigen 
and the adjuvant ASO1. This large-scale phase III trial showed 
that the RTS,S malaria vaccine, in infants results in one third 
less episodes of both clinical and severe malaria, with a good 
safety profile[6].
2.2. Blood stage vaccines
   Blood stage vaccines target the parasite’s asexual stages 
and include the use of surface antigens such as the apical 
membrane antigen-1 and merozoite surface proteins 
(MSP1,2,3). To date efficacy has been poor so the possibility 
of combining the antigens or using a viral vector are being 
considered[7].
2.3. Sexual stage vaccines
   Sexual stage vaccines stimulate antibodies that make the 
sexual stages of the parasite non-infective to mosquitoes. 
They would consist of antibodies against the antigens on 
gametes, ookinites or zygotes when ingested by the mosquito 
as part of the blood meal and prevent further development of 
the parasite in the mosquito[8]. Examples include: antigens 
Pfs25, Pfs48/45 and Pfs230[5]. These vaccines would be ideal 
in an elimination program and could also be helpful in the 
elimination of Plasmodium vivax[9]. 
   Difficulties encountered in the development of such a 
vaccine are the fact that antibodies in the blood need to be 
very high and also the concept of having to vaccinate a very 
large group of the population has no direct benefit to the 
individual[7].
   RTS,S malaria is likely to succeed in achieving the 50% 
efficacy goal, yet this level of efficacy does not justify its use 
alone, but only in combination with other control methods. 
This is also true because other methods such as insecticide-
treated nets help control other vector borne diseases including 
leishmaniasis and filariasis. A partially effective vaccine 
would be useful in areas such as parts of Asia and South 
America where vector control has been difficult due to the 
different feeding and resting habits of mosquitoes and also 
where the effective health services are not available[9].
3. Vaccines for elimination
   With the concept of malaria elimination back on the cards, 
the ideal vaccine to be used for elimination purposes would 
have to be at least 80% effective, should block transmission 
and would have to be given to the entire population rather 
than to high risk groups only[10]. Pre-erythrocytic vaccines 
such as the ones being developed by irradiation of sporozoites 
or genetic modification could have a role in blocking 
transmission and also offering some personal protection. 
Blood stage vaccines, although they decrease the levels and 
duration of parasitaemia are unlikely to have a major role. 
A combination of both a pre-erythrocytic vaccine and a 
transmission blocking vaccine could be an option.
4. Costs and dangers of vaccines
   With the development of the most promising vaccine, the 
RTS,S malaria claims to be about 30%-50% effective. May 
I query the real need and the cost effectiveness of such a 
vaccine when the currently available tools alone have been 
successful in reducing the burden of clinical malaria by 90% 
in the countries such as Zanzibar[9]. In my opinion, it will 
probably still be cost-effective in high transmission areas 
where the clinical burden of malaria is very high but then can 
such a country use its limited resources to finance a partially-
effective vaccine when it can use them for other health 
programs whilst making use of the other control methods 
already available? 
   Possible risks include the development of escape mutants 
which will not be recognized by the immune mechanisms 
of vaccinated individuals. This could result in the strains of 
higher virulence and bring back malaria and high mortality 
rates[11]. Any method of control including vaccination need to 
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be sustained and combined with a good surveillance program 
because once the burden of malaria decreases so does the 
immunity of the population. 
5. Comparing current control methods versus vaccines
5.1. Current methods of control
   Studies in Nigeria have shown that strengthening current 
methods of control will only result in a reduction in parasite 
prevalence but will not interrupt transmission[12]. I am in 
agreement with Professor Greenwood who claims that the 
widespread use of effective treatment and vector control 
could even lead to a 90% reduction of clinical malaria but 
it is unlikely that these measures alone will be able to stop 
the transmission in medium or high transmission areas[9].
In some areas of Asia and Africa, the existing methods of 
insecticide-treated nets and indoor residual spraying have 
not been enough to eliminate malaria, probably because of the 
prevalence of outdoor-resting and outdoor-biting vectors[13].
5.2. Vaccines in addition to current methods of control
   In my opinion, vaccines will be a necessary tool applied 
in conjunction with current and other innovative control 
measures. The need for a malaria vaccine is felt more in the 
face of already emerging resistance to the newer drugs such 
as the artemisinins in some areas of the Cambodia-Thailand 
border and the pyrethroids in several other countries[14,15]. 
   The malaria vaccine initiative proposes the need from a safe, 
effective and affordable malaria vaccine to close the gap left 
by other initiatives[16]. Like many others, I, however, wonder 
whether the use of some vaccines currently undergoing 
clinical trials based on development plans made several years 
ago when the focus was more on decreasing the burden of 
clinical malaria will be of any use today when we are at a stage 
where we are even considering elimination in some areas[10].
   When considering the need for a vaccine in the control of 
malaria, one must distinguish between countries with different 
levels of transmission. World Health Organization defines 3 
different stages: 
   1. Malaria control is reducing the disease burden to a level 
at which it is no longer a public health problem.
   2. Malaria elimination is interrupting local mosquito-borne 
malaria transmission in a defined geographical area, i.e. 0 
incidence of locally contracted cases.
   3. Malaria eradication is the permanent reduction to 0 of the 
worldwide incidence of malaria infection caused by a specific 
agent (i.e. a particular malaria species)[13].
6. How can we improve the control methods?
   In view of the difficulties with the development of effective 
and durable vaccines, I believe that alternative approaches 
to vaccination need to be set up as soon as possible. These 
would include the correct use of currently available tools to 
avoid encouraging resistance as well as the introduction of 
newer control methods[2].
6.1. Vector control 
   Resistance to current insecticides is on the rise, thus new 
tools and methods of application as well as newer, active and 
longer lasting products are essential. 
   Improvement in the distribution and education on the 
correct use of long-lasting insecticidal nets and insect 
repellents can help increase their use.
   Following the scaling up of the above methods during 
the control stages, they will then need to be scaled up and 
sustained even through the elimination programs.
   Broader use of larvicidal applications will be useful in 
elimination stages but current larviciding methods are not 
suitable for areas of high malaria transmission because of 
the large number of breeding sites as well as different vector 
characteristics. 
   There is still a deficiency in the tools used against outdoor-
biting vectors. The Innovative Vector Control Consortium 
constantly researches and develops improved products for 
vector control[17].
6.2. Drugs
   The appropriate treatment according to the type of 
parasites and resistance patterns in the area should be used. 
Arteminisinin-based combination therapies for Plasmodium 
falciparum and chloroquine and primaquine for Plasmodium 
vivax are the current recommended treatments[18].
   The use of monotherapy needs to be completely halted, as 
well as the sale and availability of sub-standard drugs which 
potentate resistance and do not result in an effective cure.
   There is a strong need for further research and development 
of drugs and routes which are efficacious encourage patient 
compliance and have a longer shelf life. The introduction 
of rectal artesunate for use in remote areas in cases of 
severe malaria until reaching hospital is showing promising 
results[19].
   New strategies are also required to ensure the delivery of 
new and cost-effective drugs in the right formulations to the 
populations mostly at risk including infants, young children 
and pregnant women[20]. This includes newer drugs for use in 
intermittent preventive therapy in pregnant women. Research 
is ongoing with both artemisinin-containing products as well 
as other combinations such as azithromycin/ chloroquine.
   For elimination stages, newer drugs are required that 
target asymptomatic carriers of hypnozoite stages as well 
as gametocytes. They should ideally not be limited by side 
effects such as haemolysis in patients with glucose-6-
phosphate dehydrogenase deficiencies.
6.3. Diagnostics
   Accurate diagnosis through improved, low cost rapid 
diagnostic tests with high sensitivity and specificity and good 
quality assurance are essential especially in areas where 
diagnosis by microscopy is poor. 
   Diagnostic tests to identify risk factors such as glucose-
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6-phosphate dehydrogenase deficiency prior to the 
administration of certain drugs can help make the use of 
certain drugs safer.
   Diagnostic methods to identify asymptomatic carriers 
would be useful in the elimination stages[2].
6.4. Education
   An increased awareness of the signs and symptoms of 
malaria and the seriousness of the condition is essential so 
they are able to seek the right medical attention promptly 
without delay.
   Awareness of how environmental changes such as 
deforestation and irrigation projects can create new breeding 
sites for malaria vectors is important.
   An improvement in the surveillance methods is also 
essential.
6.5. Political commitment and financing
   Despite the increase in funds, the finances available 
remain lower than the resources required to achieve global 
targets which are estimated to reach >5 billion USD by 2015[1]. 
An increase in political commitment and funds has been the 
turning point allowing such an improvement in the control 
of malaria in several counties in the last five years but these 
need to be sustained long-term.
7. Conclusion
   Malaria is a complex parasitic disease which further 
perpetuates poverty especially in the countries where it is 
highly endemic. Despite the successes achieved by some 
countries using a combination of the current control tools, 
these will one day become ineffective in the face of an 
evolving malaria parasite and drug resistance. This is also 
true because current treatment and control strategies depend 
on a very small number of compounds. There is a strong 
need for new innovative methods which should definitely 
include vaccines. Besides an effective vaccine, other research 
priorities including new drugs, insecticides and improved 
surveillance methods are also required if one is to consider 
the sustained control and the possibly elimination of malaria.
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